Efficacy of abrocitinib vs. dupilumab in adults with moderate-to-severe atopic dermatitis who had an inadequate response or intolerance to nonsteroidal immunosuppressants: results from JADE DARE

BRITISH JOURNAL OF DERMATOLOGY

WILEY

1. Pfizer Inc.